Galux, a company using AI to drive drug design, has raised $29 million to support its protein therapeutics platform. The Series B financing round brought together existing investors, including InterVest, DAYLI Partners, and PATHWAY Investment, with new investors Yuanta Investment, Korea Development Bank (KDB), SL Investment, NCORE Ventures, SneakPeek Investments, Korea Investment & Securities, and Mirae Asset Securities. The […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!